Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]-Larotinib ADME Study in Healthy Males
NCT05059743Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of larotinib in Esophageal Squamous Cell Carcinoma (ESCC), non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and 1 more, sponsored by Sunshine Lake Pharma. Primary endpoints: Cumulative excretion of 14C-labeled drug-related material at 15 days and Identification of the Proportion of different metabolites at 15 days. Started Nov 2021; status: completed.
02
Drugs
larotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT05059743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059743.